

LISTING OF CLAIMS:

This listing of claims will replace all prior versions and listings of claims in the application:

1-31. (Canceled).

32. (Currently Amended) A method of modulating the transport in a neuron of a tetanus toxin or a fusion protein comprising a fragment C of the tetanus toxin, wherein the method comprises administering to the neuron ~~a TrkB receptor agonist or a TrkB receptor antagonist~~ a Brain Derived Neurotrophic Factor (BDNF), a Neurotrophin 4 (NT-4), or Glial-Derived Neurotrophic Factor (GDNF) in an amount sufficient to thereby modulate the neuronal transport of the tetanus toxin or the fusion protein.

33. (Currently Amended) The method according to claim 32, wherein ~~the TrkB receptor agonist is administered,~~ Brain Derived Neurotrophic Factor (BDNF), Neurotrophin 4 (NT-4), or Glial-Derived Neurotrophic Factor (GDNF) thereby ~~increasing~~increases the internalization of the tetanus toxin or fusion protein at a neuromuscular junction.

34-67. (Canceled).

68. (New) The method according to claim 32, wherein the tetanus toxin is administered with Brain Derived Neurotrophic Factor (BDNF).

69. (New) The method according to claim 32, wherein the tetanus toxin is administered with Neurotrophin 4 (NT-4).

70. (New) The method according to claim 32, wherein the tetanus toxin is administered with Glial-Derived Neurotrophic Factor (GDNF).

71. (New) The method according to claim 32, wherein the fusion protein comprising a fragment C of the tetanus toxin is administered with Brain Derived Neurotrophic Factor (BDNF).

72. (New) The method according to claim 32, wherein the fusion protein comprising a fragment C of the tetanus toxin is administered with Neurotrophin 4 (NT-4).

73. (New) The method according to claim 32, wherein the fusion protein comprising a fragment C of the tetanus toxin is administered with Glial-Derived Neurotrophic Factor (GDNF).